JERUSALEM, Sept 7 (Reuters) – Shares in Israeli biotech company Protalix jumped on Sunday following a news report that its technology could be used to develop an Ebola treatment similar to the experimental drug ZMapp, which has shown promising results in recent trials.

Source: http://feeds.reuters.com/~r/reuters/AfricaNigeriaNews/~3/9MtgyY7uv6o/idAFL5N0R808920140907